TMEM106B analysis in diverse cohorts suggests no association with Parkinson’s disease risk
Henry Mauricio Chaparro-Solano, Sajanth Kanagasingam, Ziv Gan-Or, Konstantin Senkevich, on behalf of the Global Parkinson’s Genetic Program (GP2); TMEM106B
Authors
- Konstantin A. Senkevich (ORCID: https://orcid.org/0000-0003-3407-5716)
- Ziv Gan‐Or (ORCID: https://orcid.org/0000-0003-0332-234X)
- Sajanth Kanagasingam (ORCID: https://orcid.org/0009-0005-1841-1419)
- the Global Parkinson’s Genetic Program (GP2)
- Henry Mauricio Chaparro-Solano (ORCID: https://orcid.org/0000-0002-1649-7854)
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Cleveland Clinic (US)
- Universidad Autónoma de Bucaramanga (CO)
- McGill University Health Centre (CA)
- Cleveland Clinic Lerner College of Medicine (US)
- Cleveland Clinic Research (US)
- McGill University (CA)
- Case Western Reserve University (US)
Publication Details
- Journal
- Brain
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1093/brain/awag411
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Yale University
- American Parkinson Disease Association
- Celgene
- McGill University
- Verily Life Sciences
- Ministério da Ciência, Tecnologia e Inovação
- Canada First Research Excellence Fund
- Fulbright Colombia
- Alliance de recherche numérique du Canada
- National Institutes of Health
- Fonds de Recherche du Québec - Santé
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke